Description

Contest celebrates scientific breakthroughs with $15,000 research grant

Cambridge UK, February 3, 2014: Abcam plc, a global leader in the supply of innovative protein research tools, today announced Yali Huang as the winner of its 15 discoveries contest. Ms. Huang conducts her work at the Early Embryo Development lab at the MRC Centre of Regenerative Medicine, University of Edinburgh, Scotland. The contest recognises the most innovative and exciting scientific breakthroughs of the last 18 months supported by Abcam products.

In recognition of her winning entry, Ms. Huang’s lab will receive a $15,000 lab research grant and $1,000 worth of Abcam products. Her project, titled ‘In Vivo Differentiation Potential of Epiblast Stem Cells Revealed by Chimeric Embryo Formation’, was selected from over 80 global submissions by an expert panel of scientists. Illustrating the importance of the host environment on Chimera formation, the research contributes to a greater understanding of how cultured stem cells relate to the early embryo.

Ms. Huang said: “We’re delighted to have won the 15 discoveries contest and would like to thank Abcam for their support in making our research project a success. At a time when budgets are under pressure the grant will be extremely beneficial to our lab, to help us further our discoveries.”

Dr Jonathan Milner, CEO, Abcam, said: “The 15 discoveries contest is Abcam’s way of recognising the hard work and achievements of life science researchers. We are fortunate to live in a time where, thanks to great advances in biology tools and techniques,  researchers are able to make almost daily breakthroughs in our understanding of how cells operate in health and disease. Abcam’s goal is to continue supporting these breakthroughs, enabling scientists to discover more.”

Abcam is committed to supporting scientists with their life science discoveries and continually looks at new ways to innovate its products and services. This includes development of pioneering research tools such as its proprietary rabbit monoclonal antibody technology, RabMAb®.